2024-07-29 09:00:13
Where will Doliprane end? While President Emmanuel Macron has made paracetamol the symbol of the Government’s health recovery policy, Sanofi is preparing to say goodbye to the little yellow box with the symbol, which it inherited twenty years ago during the acquisition of Aventis. Enough to create a conflict between the government and the French leader of the pharmaceutical industry.
The laboratory announced in October 2023 its plan to soon separate from Opella (5.2 billion euros in turnover in 2023), a subsidiary of non-prescription drugs, which is around a hundred products, including pain star of French pharmacies.
“We told Sanofi that we don’t want them to sell Opella. However Sanofi maintains its intention to sell”we commented on Bercy, who warned that he would look “the way you need it” to preserve the productive forces on the national soil. “Paracetamol made in France must be available in France”we are adding to the ministry.
Several candidates for takeover
The issue is reminiscent of that made with regard to the Servier laboratory, which plans to launch Biogaran, the number one generic drug in France. “Our project does not have the same approach with the end of Doliprane in France”wants to confirm, Thursday July 25, François-Xavier Roger, financial director of Sanofi, on the occasion of the presentation of the half-year results of the group.
To prevent the dispute, Sanofi will consider maintaining a stake in its subsidiary by retaining a significant portion of Opella’s capital. In the event of a sale to a private player – another scenario considered is that of an IPO – the hospital can retain, depending on the options studied, 30% or almost 50% of the capital of the health division customer.
The laboratory has not yet decided on the terms of the departure of its subsidiary, but the latter seems to show interest. “The good news is that the process is very competitive between these different options anyway”underlined Mr. Roger to investors.
Several takeover candidates, including the French investment fund PAI or the American Advent, which has paid 1.9 billion euros in 2018 to get their hands on Zentiva, the former generic drug subsidiary of Sanofi, will have submitted indicative offers in mid-July.
#sale #Doliprane #created #conflict #Sanofi #Bercy